Piper Sandler reiterates Oklo stock rating on reactor progress

Piper Sandler has maintained an Overweight rating and $55.00 price target on Oklo (NYSE:OKLO) stock after visiting their Groves facility. The stock is currently trading at $36.74, close to its 52-week low of $34.38 and down 68% over the past year. While the Pro Research Report suggests the stock may be overvalued, Piper Sandler's visit reinforced their confidence that Oklo can bring a nuclear project from a greenfield site to first criticality on schedule.

The 11-month journey from ground breaking to criticality at Groves, on private land, serves as strong evidence of the company's execution capabilities. The development does not impact the firm's financial projections for Oklo. The company's targeted Aurora project, a 75 megawatt sodium-cooled reactor, is slated for Idaho National Laboratory in 2028.

Groves is not testing the reactor design, fuel, or the Nuclear Regulatory Commission path, as these areas pose the majority of Aurora's risk. Piper Sandler highlights the early 2027 investor day as the next catalyst for the stock. In recent news, Oklo reported a wider-than-expected second-quarter loss but beat revenue forecasts, delivering an adjusted EPS of -$0.28 and revenue of $1.2 million.

The company has $3.0 billion in cash and marketable securities and announced a potential $1 billion at-the-market stock offering with Goldman Sachs and J.P. Morgan as sales agents. However, Oklo's stock has faced price adjustments from other analysts. Truist Securities lowered its target to $51, citing cost clarity concerns while maintaining a Hold rating.

UBS reduced its target from $55 to $41, keeping a Neutral rating, reflecting changes in their long-term financial projections. Despite these adjustments, Oklo remains active in its business segments, including Power, Fuel, and Isotopes, with recent progress including criticality at Groves and advancements in securing a long-term fuel supply.